MedTrace Logo

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

NCT00385593 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 654

Last updated 2010-12-16

Study results available
· View outcomes & findings →

Summary

This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA).

Conditions

  • Asthma, Bronchial

Interventions

DRUG

Symbicort (budesonide/formoterol) Turbuhaler

DRUG

Conventional treatment

Sponsors & Collaborators

Principal Investigators

  • Carlos Barcina, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2008-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00385593 on ClinicalTrials.gov